2014
Novel Molecules
Vukelic V, Orias M. Novel Molecules. Clinical Hypertension And Vascular Diseases 2014, 47-55. DOI: 10.1007/978-1-4939-1982-6_5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAngiotensin II type 2 receptor agonistType 2 receptor agonistBlood pressure controlEnd-organ damageEndothelin receptor antagonistsAldosterone synthase inhibitorsNew therapeutic approachesSoluble epoxide hydrolase inhibitorsSoluble guanylyl cyclaseEpoxide hydrolase inhibitorAldosterone axisHypertension treatmentVasopeptidase inhibitorReceptor antagonistReceptor agonistRecombinant renalaseTherapeutic approachesNew agentsSynthase inhibitorAnimal modelsRenin inhibitorsPressure controlGuanylyl cyclaseAdverse effectsHydrolase inhibitors
2009
Is there a role for direct renin inhibitors in chronic kidney disease?
Peixoto AJ, Orias M. Is there a role for direct renin inhibitors in chronic kidney disease? Current Opinion In Nephrology & Hypertension 2009, 18: 397-403. PMID: 19584722, DOI: 10.1097/mnh.0b013e32832e3183.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseBlood pressure controlKidney disease progressionRenin inhibitorsCardiovascular eventsKidney diseaseDisease progressionEffective blood pressure controlPressure controlHard renal endpointsEarly diabetic nephropathyNormal renal functionDirect renin inhibitorRandomized clinical trialsRenal endpointsStudy drugCardiovascular riskDiabetic nephropathyRenal functionRenal injuryImproved survivalClinical trialsAnimal modelsHuman studiesPatients